Linscomb & Williams Inc. Boosts Position in Pfizer Inc. (PFE)

Linscomb & Williams Inc. increased its position in Pfizer Inc. (NYSE:PFE) by 1.8% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 140,234 shares of the biopharmaceutical company’s stock after purchasing an additional 2,517 shares during the period. Linscomb & Williams Inc.’s holdings in Pfizer were worth $5,088,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of PFE. Ballew Advisors Inc bought a new position in Pfizer in the first quarter worth about $102,000. W.G. Shaheen & Associates DBA Whitney & Co bought a new position in Pfizer in the first quarter worth about $132,000. Braun Bostich & Associates Inc. bought a new position in Pfizer in the first quarter worth about $139,000. Bray Capital Advisors bought a new position in Pfizer in the first quarter worth about $139,000. Finally, Clearwater Capital Advisors LLC bought a new position in Pfizer in the first quarter worth about $156,000. Institutional investors and hedge funds own 69.01% of the company’s stock.

In related news, major shareholder Pfizer Inc acquired 55,556 shares of the stock in a transaction that occurred on Monday, October 15th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the purchase, the insider now directly owns 21,976,484 shares of the company’s stock, valued at $395,576,712. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Loretta V. Cangialosi sold 26,814 shares of the firm’s stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $40.16, for a total transaction of $1,076,850.24. Following the transaction, the vice president now owns 102,360 shares in the company, valued at approximately $4,110,777.60. The disclosure for this sale can be found here. Insiders have sold 234,096 shares of company stock worth $9,366,617 in the last quarter. Company insiders own 0.06% of the company’s stock.

PFE opened at $43.23 on Tuesday. The company has a market cap of $253.59 billion, a PE ratio of 16.31, a price-to-earnings-growth ratio of 2.18 and a beta of 0.96. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41. Pfizer Inc. has a twelve month low of $33.20 and a twelve month high of $45.81.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.07. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The business had revenue of $13.47 billion for the quarter, compared to analyst estimates of $13.30 billion. During the same quarter last year, the business earned $0.67 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.15%. Pfizer’s dividend payout ratio is presently 51.32%.

A number of brokerages have issued reports on PFE. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, July 15th. BMO Capital Markets reaffirmed a “buy” rating and set a $42.00 price target on shares of Pfizer in a report on Thursday, July 19th. Jefferies Financial Group reaffirmed a “neutral” rating and set a $39.00 price target on shares of Pfizer in a report on Monday, July 9th. Morningstar set a $46.00 price target on Pfizer and gave the company a “neutral” rating in a report on Tuesday, October 9th. Finally, Cantor Fitzgerald set a $45.00 price target on Pfizer and gave the company a “buy” rating in a report on Tuesday, July 31st. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $42.80.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Article: Trading Strategy Methods and Types

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply